Authors
Latest:
Improving Care in Multiple Myeloma: Unmet Needs and Future DirectionsClosing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.
Latest:
Dr Chari on the Selection of BCMA-Targeted Therapies Within Multiple MyelomaAjai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.
Latest:
Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple MyelomaAjay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Latest:
Dr Nooka on Integrating Bispecific Antibodies Into the Community Treatment Paradigm for Multiple MyelomaAjay K. Nooka, MD, MPH, FACP, discusses the integration of bispecific antibodies into the community treatment paradigm for multiple myeloma.
Latest:
CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPCAjay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.
Latest:
New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI MetastasesDespite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.
Latest:
Dr. Alva on the Shift Toward Combination Therapy in mRCCAjjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Latest:
Staying Afloat When the Floodgates OpenIt is quite easy to be drowned in the rising floodwaters of hematology and medical oncology, especially when you start training.
Latest:
Dr. Patnaik on Challenges With Sequencing Therapies in mCRPCAkash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Targeted Therapies in Advanced Renal Cell Cancer: A Critical ReviewIn order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.
Latest:
Dr. Shimomura Discusses the HERB TEA Study in HER2+ Breast CancerAkihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.
Latest:
International Hematology/Oncology Elective: A Unique Learning ExperienceAlthough minor institution-specific variations exist, traditional fellowship programs in the United States are able to provide training in the sophisticated Western style of practice.
Latest:
Dr. Puri on Challenges With Treating Older Patients With Pancreatic CancerAkshjot Puri, MD, discusses challenges facing older patients with pancreatic cancer.
Latest:
Dr. Benson on the Complexity of Up-front Treatment in HCCAl B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.
Latest:
Dr. Algazi on Benefit of Continuous Dabrafenib/Trametinib Dosing in BRAF+ MelanomaAlain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.
Latest:
Dr. Mita on Emergence of Checkpoint Inhibitors SCLCAlain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.
Latest:
Practice in South Texas Offers Vertically Integrated Cancer CareProviding comprehensive, compassionate, cost-effective care has been the guiding principle of Urology San Antonio. The practice manages over 200,000 visits and establishes relationships with more than 22,000 new patients each year.
Latest:
Healthcare IT Still Seeks a Security BlanketAugust has traditionally been a sleepy month for government regulatory agencies, but this year, Washington's usual summer torpor was interrupted by a rush of new initiatives, as more than three-quarters of a trillion dollars from the American Recovery and Reinvestment Act surged into a mind- boggling range of projects.
Latest:
IO Therapy in mCRPC and Clinical PearlsBefore sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.
Latest:
Krebs Cycle: A Role for Metabolic Enzymes in Acute Myeloid LeukemiaOne promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.
Latest:
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MDHear Alan P. Venook, MD, discuss recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal cancers.
